Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Enveric Biosciences, Inc. ENVB

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-8.8M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2019 · Revenue 39.9 · Net income -2.4
20M40M-10M-20M
201020132016201920222025
Compound annual growth
+3.4%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2018 · Operating -16.6% · Net -39.3%
-10%-20%-30%
201020172025
ROE
FY2025 · ROE -304.0%
-200%-400%
201020172025
Three returns, three denominators.

Each USD of equity lost 304 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -14.1
-10M-20M
201020172025

Total assetsUSD 5.1M
EquityUSD 4.2M
Current ratio5.38×

Equity funds 82% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ENVB, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B◌◌◌◌◌◌0.00.00.00.00.0◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.1◌◌◌◌−0.0−0.0◌◌◌◌◌
Income tax $B◌0.00.0−0.0−0.0◌0.00.0−0.0−0.0−0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌−0.0−0.0−0.0◌◌◌◌◌◌◌◌◌◌◌
EPS, diluted $−36.24−228.48−121.29−13.00−2.07−1.19−0.46−20.47−0.75−0.21−0.070.000.000.000.00−0.01
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−304.0−539.6−208.0−99.9−380.8———−58.3−46.6——————
Shares out B0.000.000.000.000.030.010.000.040.020.010.010.020.010.010.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Eight checks were skipped: revenue is not tagged before 2015. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image